3-(4-fluorophenyl)-5-phenylacetylamino-4-(4-pyridyl)pyrazole | 277746-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-fluorophenyl)-5-phenylacetylamino-4-(4-pyridyl)pyrazole
• 英文别名: 5-(4-Fluorophenyl)-3-phenylacetylamino-4-(4-pyridyl)pyrazole；N-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-pyrazol-3-yl]-2-phenylacetamide
• CAS: 277746-28-8
• 化学式: C₂₂H₁₇FN₄O
• 分子量: 372.402
• InChiKey: BDSZOAWKWSYMDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,5-二氧代吡咯烷-1-基4-氟苯甲酸 在 potassium carbonate 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.5h， 生成 3-(4-fluorophenyl)-5-phenylacetylamino-4-(4-pyridyl)pyrazole
  参考文献：
  名称：

  Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept

  摘要：

  Inhibitors of p38 mitogen-activated protein (MAP) kinase, which are closely involved in the production of inflammatory cytokines, are considered promising curative drugs for chronic inflammatory disorders. However, there is also a growing concern regarding its systemic side effects. To reduce the occurrence of side effects, we have identified a novel p38 MAP kinase inhibitor that shows properties of an antedrug, which imparts its effect solely on the inflammatory site and is metabolically inactivated right after. We have designed isoxazole derivatives through the addition of a fresh interacting fourth site to the structure of the prototypical p38 MAP kinase inhibitor that harbors three point interactive sites. The derivative 26d (AKP-001) shows excellent p38 MAP kinase inhibitory activity and a high selectivity for various kinases. Its rapid metabolism has been confirmed in rats. Moreover, 26d has been shown to be effective in animal models of inflammatory bowel disease.

  DOI：

  10.1016/j.bmc.2014.05.045

文献信息

• Aminopyrazole derivatives
  申请人：Teikoku Hormone Mfg. Co., Ltd.

  公开号：US06511997B1

  公开（公告）日：2003-01-28

  Aminopyrazole derivatives represented by formula (I), or salts thereof, wherein X1 and X2 are each a hydrogen atom or a halogen atom, or X1 and X2 may be united together to form a lower alkylenedioxy group, Q is a pyridyl group or a quinolyl group, R1 is a hydrogen atom, a substituted or unsubstituted lower alkyl or aryl group, R2 is a hydrogen atom, a lower alkyl group, or an aralkyl group, and R3 represents a hydrogen atom, an organic sulfonyl group, or —C(═Y)—R4 in which R4 is a hydrogen atom or an organic residue and Y is an oxygen or sulfur atom, provided that, when R3 is a hydrogen atom, R1 is a group other than a hydrogen atom and R2 is a hydrogen atom. These amimopyrazole derivatives or their salts have excellent p38MAP kinase inhibiting activities and are hence useful in the prevention or treatment of diseases associated with tumor necrosis sis factor &agr;, interleukin 1, interleukin 6 or cyclooxygenase II.

  Aminopyrazole衍生物的化学式(I)或其盐，其中X1和X2分别为氢原子或卤素原子，或X1和X2可以结合在一起形成较低的烷二氧基基团，Q为吡啶基团或喹啉基团，R1为氢原子、取代或未取代的较低烷基或芳基，R2为氢原子、较低烷基或芳基，R3代表氢原子、有机磺酰基团，或—C(═Y)—R4，其中R4为氢原子或有机残基，Y为氧原子或硫原子，前提是当R3为氢原子时，R1是除氢原子以外的基团，且R2为氢原子。这些氨基吡唑衍生物或其盐具有优异的p38MAP激酶抑制活性，因此在预防或治疗与肿瘤坏死因子&agr;、白细胞介素1、白细胞介素6或环氧合酶II相关的疾病中非常有用。
• Treating agent of inflammatory bowel disease
  申请人：Hasumi Koichi

  公开号：US20090192164A1

  公开（公告）日：2009-07-30

  The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.

  本发明揭示了治疗炎症性肠病的治疗剂，其包含具有抗药性质的p38MAPkinase抑制剂作为活性成分。
• AMINOPYRAZOLE DERIVATIVES
  申请人：TEIKOKU HORMONE MFG. CO., LTD.

  公开号：EP1142890A1

  公开（公告）日：2001-10-10

  Aminopyrazole derivatives represented by formula (I), or salts thereof, wherein X1 and X2 are each a hydrogen atom or a halogen atom, or X1 and X2 may be united together to form a lower alkylenedioxy group, Q is a pyridyl group or a quinolyl group, R1 is a hydrogen atom, a substituted or unsubstituted lower alkyl or aryl group, R2 is a hydrogen atom, a lower alkyl group, or an aralkyl group, and R3 represents a hydrogen atom, an organic sulfonyl group, or -C(=Y)-R4 in which R4 is a hydrogen atom or an organic residue and Y is an oxygen or sulfur atom, provided that, when R3 is a hydrogen atom, R1 is a group other than a hydrogen atom and R2 is a hydrogen atom. These aminopyrazole derivatives or their salts have excellent p38MAP kinase inhibiting activities and are hence useful in the prevention or treatment of diseases associated with tumor necrosis factor α, interleukin 1, interleukin 6 or cyclooxygenase II.

  由式(I)代表的氨基吡唑衍生物或其盐，其中X1和X2各自为氢原子或卤原子，或X1和X2可结合在一起形成低级亚烷基二氧基，Q为吡啶基或喹啉基，R1为氢原子、取代或未取代的低级烷基或芳基、R2 是氢原子、低级烷基或芳烷基，R3 代表氢原子、有机磺酰基或-C(=Y)-R4，其中 R4 是氢原子或有机残基，Y 是氧原子或硫原子，但当 R3 是氢原子时，R1 是氢原子以外的基团，R2 是氢原子。这些氨基吡唑衍生物或其盐类具有优异的 p38MAP 激酶抑制活性，因此可用于预防或治疗与肿瘤坏死因子 α、白细胞介素 1、白细胞介素 6 或环氧合酶 II 有关的疾病。
• TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP2044957A1

  公开（公告）日：2009-04-08

  The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.

  本发明公开了治疗炎症性肠病的药物，其活性成分含有具有抗药性的 p38MAPkinase 抑制剂。
• US6511997B1
  申请人：——

  公开号：US6511997B1

  公开（公告）日：2003-01-28